A pilot study of oral L-arginine in cystic fibrosis.
Exhaled nitric oxide has previously been found to be low in cystic fibrosis. The aim of this study was to determine whether exhaled nitric oxide levels would increase in response to oral L-arginine supplementation administered daily for 4 weeks. Exhaled and nasal nitric oxide was measured weekly. Plasma L-arginine levels increased in response to supplementation but this was not reflected in an increase in eNO levels.
Everard
M L
ML
m.l.everard@sheffield.ac.uk
Donnelly
D
D
D000284:Administration, Oral; D000293:Adolescent; D001120:Arginine / Q000008:administration & dosage*; D001944:Breath Tests; D002648:Child; D003550:Cystic Fibrosis / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D008297:Male; D009419:Nerve Tissue Proteins / Q000378:metabolism; D009569:Nitric Oxide / Q000032:analysis; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052248:Nitric Oxide Synthase Type I; D052250:Nitric Oxide Synthase Type III; D010865:Pilot Projects; D016896:Treatment Outcome; D014797:Vital Capacity / Q000502:physiology
D009419:Nerve Tissue Proteins; D009569:Nitric Oxide; D001120:Arginine; C496320:NOS1 protein, human; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052248:Nitric Oxide Synthase Type I; D052250:Nitric Oxide Synthase Type III